GBI Research, May 2010, Pages: 82
“Pharmaceutical Research and Development (R&D) - Increasing Efficency Through Information Technology and Externalization” provides key data, information and analysis on major pharmaceuticalR
BioPolaris, March 2010, Pages: 1
Albiglutide - R & D Biopharmaceutical & Pharmaceutical Product Profile
albiglutide (Syncria®, Albugon, GSK716155) is a late-stage R & D therapeutic product
Sources of Information:
Research data
BioPolaris, March 2010, Pages: 2
Taspoglutide - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Taspoglutide (BIM 51077, ITM-077, RG1538, RO5073031) is a late-stage R & D therapeutic product.
Sources of Information
BioPolaris, March 2010, Pages: 1
VIAject® - R & D Biopharmaceutical & Pharmaceutical Product Profile.
VIAject® is a late-stage R & D therapeutic product.
Research data published in this product profile are obtained primarily from
BioPolaris, March 2010, Pages: 1
UNI-rE-4 (rExendin-4) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
UNI-rE-4 (rExendin-4) is a late-stage R & D therapeutic product.
Research data published in this product profile
GBI Research, Sep 2011, Pages: 153
“Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity” which provides insights into the licensing agreements of large
Decision Resources, Inc., Sep 2009, Pages: 24
Can radical changes to the structures and strategies of pharmaceuticalR&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity
BioPolaris, March 2010, Pages: 2
Alogliptin (SYR-322) - R & D Biopharmaceutical & Pharmaceutical Product Profile
alogliptin (SYR-322) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published
BioPolaris, March 2010, Pages: 3
LY2189265 - R & D Biopharmaceutical & Pharmaceutical Product Profile.
LY2189265 is a late-stage R & D therapeutic product.
Sources of Information:
Research data published in this product profile
BioPolaris, March 2010, Pages: 2
Linagliptin (Ondero®, BI 1356) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Linagliptin (Ondero®, BI 1356) is a late-stage R & D therapeutic product.
Sources of Information
BioPolaris, March 2010, Pages: 2
IN-105 - R & D Biopharmaceutical & Pharmaceutical Product Profile
IN-105 is a late-stage R & D therapeutic product.
Sources of Information:
Research data published in this product profile
BioPolaris, March 2010, Pages: 2
Vildagliptin (Galvus®, LAF237) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Vildagliptin (Galvus®, LAF237) is a late-stage R & D therapeutic product.
Sources of Information
BioPolaris, March 2010, Pages: 2
Ranirestat (AS-3201) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Ranirestat (AS-3201) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published
BioPolaris, March 2010, Pages: 1
Cetilistat (ATL-962) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Cetilistat (ATL-962) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published
BioPolaris, March 2010, Pages: 1
Rivoglitazone (CS-011, DE-101) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Rivoglitazone (CS-011, DE-101) is a late-stage R & D therapeutic product.
Sources of Information
BioPolaris, March 2010, Pages: 1
Balaglitazone (DRF 2593, NN2344) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Balaglitazone (DRF 2593, NN2344) is a late-stage R & D therapeutic product.
Sources of Information
BioPolaris, March 2010, Pages: 1
Oral-lyn (Oral Recosulin) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Oral-lyn (Oral Recosulin) is a late-stage R & D therapeutic products.
Sources of Information:
Research data
BioPolaris, March 2010, Pages: 1
HDV-Insulin (HDV-I) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
HDV-Insulin (HDV-I) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published
Venture Planning Group, Oct 2010, Pages: 160
- Pfizer
- Roche
- Sanofi-Aventis
- Wyeth The 2011 Leading Pharmaceutical Companies R&D Expenditures and Major Programs
